Skip to main content
. 2016 Jan 11;6:19042. doi: 10.1038/srep19042

Figure 2.

Figure 2

Inhibition of 26D1 (a) and H16.V5 (b) binding to HPV16 VLP by pre-binding of heparin. Insets: dose response curves showing the inhibition of 26D1 or H16.V5 binding by the soluble receptor molecule heparin in solution. The median inhibitory concentration (IC50) values for 26D1 (40 mg/ml) and H16.V5 (100 mg/ml) were approximated by linear regression fitting the data (inhibition rate vs. heparin concentration) from multiple runs (n = 6).